Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 16/20 | 0.53 |
| ▸ | GUCY1B1 | Q02153 | 16/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781763 | 1.00 | GUCY1A1 (0.53) | GUCY1A1GUCY1B1KEAP1NFE2L2PTGER1 | |
| SCHEMBL1781761 | 1.00 | GUCY1A1 (0.53) | GUCY1A1GUCY1B1KEAP1NFE2L2PTGER1 | |
| SCHEMBL1781798 | 1.00 | GUCY1A1 (0.53) | GUCY1A1GUCY1B1KEAP1NFE2L2PTGER1 | |
| SCHEMBL12603767 | 1.00 | GUCY1A1 (0.53) | GUCY1A1GUCY1B1KEAP1NFE2L2PTGER1 | |
| SCHEMBL12603771 | 0.92 | GUCY1A1 (0.44) | GUCY1A1GUCY1B1KEAP1NFE2L2PTGER1 | |
| SCHEMBL1780191 | 0.92 | GUCY1A1 (0.44) | GUCY1A1GUCY1B1KEAP1NFE2L2PTGER1 | |
| SCHEMBL1780532 | 0.92 | GUCY1A1 (0.54) | GUCY1A1GUCY1B1KEAP1NFE2L2 | |
| SCHEMBL1780529 | 0.92 | GUCY1A1 (0.54) | GUCY1A1GUCY1B1KEAP1NFE2L2 | |
| SCHEMBL1780193 | 0.92 | GUCY1A1 (0.44) | GUCY1A1GUCY1B1KEAP1NFE2L2PTGER1 | |
| SCHEMBL1781338 | 0.92 | GUCY1A1 (0.44) | GUCY1A1GUCY1B1KEAP1NFE2L2PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023246-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-27 | — | — | US | disclosed |
| US-11166932-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-09 | — | — | US | disclosed |
| EP-3325013-B1 | STIMULATORS / ACTIVATORS OF SOLUBLE GUANYLAT CYCLASE IN COMBINATION WITH A NEP-INHIBITOR AND/OR AN ANGIOTENSIN AII-ANTAGONIST AND THE USE THEREOF | Bayer Pharma AG (DE) | 2020-09-23 | — | — | EP | disclosed |
| EP-3291811-B1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-20190125709-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-02 | — | — | US | disclosed |
| US-10265314-B2 | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-04-23 | — | — | US | disclosed |
| US-10189856-B2 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | ADVERIO PHARMA GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| WO-2016177660-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | disclosed |
| US-20130035340-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-07 | — | — | US | disclosed |
| WO-2011161099-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011147810-A1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011095553-A1 | SGC STIMULATORS OR SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011095534-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-11 | — | — | WO | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| WO-2009032249-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK & CO., INC. (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035340-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | PDE5A, PDE3B, PDE3A | GUCY1A1 5/4885GUCY1B1 6/4885KEAP1 2298/4885 |
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | PDE5A, PDE2A, PDE3A | GUCY1A1 11/4885GUCY1B1 15/4885KEAP1 2575/4885 |
| US-10265314-B2 | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis | PDE5A, GMPS, PDE3A | GUCY1A1 9/4885GUCY1B1 8/4885KEAP1 3074/4885 |
| US-20190125709-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | MME, ECE1, REN | GUCY1A1 8/4885GUCY1B1 16/4885KEAP1 1852/4885 |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A2, GUCY1A1 | GUCY1A1 3/4885GUCY1B1 1/4885KEAP1 2477/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | GUCY1A1 3/4885GUCY1B1 1/4885KEAP1 2477/4885 |
| US-10189856-B2 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | PDE5A, PDE3A, PDE2A | GUCY1A1 6/4885GUCY1B1 10/4885KEAP1 2252/4885 |
| US-11166932-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | MME, ECE1, REN | GUCY1A1 8/4885GUCY1B1 16/4885KEAP1 1852/4885 |
| US-20220023246-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | MME, ECE1, REN | GUCY1A1 8/4885GUCY1B1 16/4885KEAP1 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.